MYND Life Sciences Statistics
MYND Life Sciences (MYNDF) Stock Statistics & Valuation Metrics
Total Valuation
MYND Life Sciences has a market cap or net worth of $2.35M. The enterprise value is $6.35T.
- Market Cap
- $2.35M
- Enterprise Value
- $6.35T
Share Statistics
MYND Life Sciences has 47,817,180 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 47,817,180
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
MYND Life Sciences’s return on equity (ROE) is 0.30 and return on invested capital (ROIC) is 91.43%.
- Return on Equity (ROE)
- 0.30
- Return on Assets (ROA)
- -1.90
- Return on Invested Capital (ROIC)
- 91.43%
- Return on Capital Employed (ROCE)
- 0.36
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of MYND Life Sciences is -2.18. MYND Life Sciences’s PEG ratio is -0.01.
- PE Ratio
- -2.18
- PS Ratio
- 0.00
- PB Ratio
- -0.66
- Price to FCF
- -16.88
- Price to Operating Cash Flow
- -16.69
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, MYND Life Sciences had revenue of 0 and earned -1.52M in profits. Earnings per share was -0.03.
- Revenue
- 0
- Gross Profit
- -332.99K
- Operating Income
- -1.81M
- Pretax Income
- -1.52M
- Net Income
- -1.52M
- EBITDA
- -1.81M
- Earnings Per Share (EPS)
- -0.03
Cash Flow
In the last 12 months, operating cash flow was -172.78K and capital expenditures 4, giving a free cash flow of -172.77K billion.
- Operating Cash Flow
- -172.78K
- Free Cash Flow
- -172.77K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
MYND Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.92%
- Earnings Yield
- -45.87%
Stock Price Statistics
- Beta
- 3.20
- 52-Week Price Change
- 61.54%
- 50-Day Moving Average
- 0.02
- 200-Day Moving Average
- 0.02
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
MYND Life Sciences upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Sep 25, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
MYND Life Sciences as a current ratio of 0.14, with Debt / Equity ratio of -60.28%
- Current Ratio
- 0.14
- Quick Ratio
- 0.14
- Debt to Market Cap
- 4.23
- Net Debt to EBITDA
- -1.64
- Interest Coverage Ratio
- -2.48
Taxes
In the past 12 months, MYND Life Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
MYND Life Sciences EV to EBITDA ratio is -3.51, with an EV/FCF ratio of -32.01.
- EV to Sales
- 0.00
- EV to EBITDA
- -3.51
- EV to Free Cash Flow
- -32.01
- EV to Operating Cash Flow
- -32.01
Balance Sheet
MYND Life Sciences has $497.00 in cash and marketable securities with $3.00M in debt, giving a net cash position of -$3.00M billion.
- Cash & Marketable Securities
- $497.00
- Total Debt
- $3.00M
- Net Cash
- -$3.00M
- Net Cash Per Share
- -$0.06
- Tangible Book Value Per Share
- -$0.13
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for MYND Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
